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Abstract
Cortexolone 17α-propionate, also known as clascoterone, is a potent androgen receptor inhibitor intended for the
topical treatment of skin diseases associated with androgenic pathway alterations. In nonclinical studies, cortexolone
17α-propionate was found to have a weak inhibitory effect on human Ether-à-go-go-Related Gene (hERG) potassium
channels, which are vital for normal electrical activity in the heart.When used in a cream formulation, little cortexolone
17α-propionate is absorbed. However, the solution formulation developed for the treatment of androgenetic alopecia
leads to a measurable systemic concentration and accumulation of the antiandrogen. This phase 1 study assessed
the effect of cortexolone 17α-propionate on the QTc interval using concentration-effect analysis and the effect of
a meal on QTc to confirm assay sensitivity. Thirty-two volunteers were randomly assigned to receive the active
drug or a matching vehicle as placebo. Participants were dosed twice daily on days 1 to 3 (225 mg applied topically
as a 7.5% solution 12 hours apart) and once on day 4. Pharmacokinetic and electrocardiogram assessments were
performed after supratherapeutic doses. Assay sensitivity was successfully confirmed by using the food effect on the
QTc interval. The results of this concentration-QTc analysis demonstrate that cortexolone 17α-propionate and its
metabolite/degradation product had no effect on the QTc interval in the concentration range tested.
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Cortexolone 17α-propionate (Figure S1) is a topical
androgen receptor inhibitor with weak glucocorticoid
effects currently being developed by Cassiopea S.p.A
(Lainate, Italy) for the treatment of androgenetic
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alopecia (AGA) and acne. It exerts local antiandro-
genic activity by binding human androgen receptors
to displace endogenous androgenic hormones1 and is
rapidly metabolized in plasma into cortexolone (also
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known as 11-deoxycortisol)—a naturally occurring
corticosteroid.2
The use of available topical and oral antiandro-
genic therapies for AGA and acne is currently limited
because of undesirable systemic side effects, such as
reduced libido, impairment of spermatogenesis, and
feminization of male fetuses in pregnant women.3,4
Cortexolone 17α-propionate has been designed as a
topical androgen receptor inhibitor with comparable
efficacy to minoxidil for the treatment of AGA5 and
tretinoin for the treatment of acne,6,7 but without
the significant systemic activity seen with currently
available oral antiandrogenic therapies.
Inhibition of human Ether-à-go-go-Related Gene
(hERG) potassium channels causes QT interval pro-
longation and can lead to life-threatening ventricular
arrhythmias.8 QT prolongation is a potential concern
with any antiandrogenic drug, given that testosterone,
a major endogenous androgen, appears to shorten the
QTc interval.9,10 At the same time, there is little re-
search into the effects of antiandrogenicmedications on
the QT interval. One study in elderly male patients on
antitestosterone treatment found little evidence of any
QT-prolonging effect.11 Similarly, research by Sarib-
ayev et al (2014) suggested that corticosteroids have
a QT-shortening effect because of the activation of
potassium channels through glucocorticoid signaling in
cardiac myocytes.12
In vitro assays investigating the effect of cortex-
olone 17α-propionate on hERG potassium channels
found the compound to inhibit hERG weakly in a
dose-dependent manner ranging from 2.6% to 40% at
concentrations of 1 × 10–8 M (corresponding to a Cmax
of 4 × 10–3 μg/mL) to 3 × 10–5 M.13 Subsequently, an
in vivo safety pharmacology study was carried out in
beagle dogs, which were attached to cardiac telemetry
devices and administered subcutaneous doses of cor-
texolone 17α-propionate. This study found no effects
on arterial blood pressure, heart rate, body temperature,
or QT interval at 10, 50, and 250 mg/kg (data available
on request). However, the findings require further
investigation to determine the effects of cortexolone
17α-propionate on the QT interval in humans.
To date, clinical studies testing the 1% cream formu-
lation have not resulted in significant systemic exposure,
and it has been suggested that studies using a 5% so-
lution (50 mg per application) would therefore provide
sufficient exposures applicable to both the cream and
solution formulation. In a 28-day study testing multi-
ple daily applications of a cortexolone 17α-propionate
5% solution in healthy volunteers, maximum mean
plasma concentrations of 3.63 ng/mL were observed
that were similar to the lowest in vitro concentration
that previously led to hERG inhibition. The authors
did not detect any adverse cardiovascular signals.1 The
downstream metabolites, cortexolone 21-propionate,
and cortexolone are both 21-hydroxysteroids. Cortex-
olone 21-propionate has not been explored in terms
of pharmacological activity, and cortexolone is an
intermediate in the biosynthesis of cortisol.13
However, none of these studies were specifically
designed to evaluate the cardiac safety of cortexolone
17α-propionate using high-quality electrocardiograms
(ECGs) and plasma concentration measurements
for the analysis of concentration effects required to
demonstrate the absence of an effect on the QT interval
consistent with the International Council for Har-
monization (ICH) E14 (R3) guidelines.14 In addition,
given the potential for patients to dose themselves in
excess of doses recommended in clinical use, a cardiac
safety study was deemed necessary to examine any QT
interval effects of cortexolone 17α-propionate and its
metabolites/degradation products at supratherapeutic
exposures.
Here, we describe the results of a phase 1 study inves-
tigating the effects of cortexolone 17α-propionate on
the QTc interval at supratherapeutic doses in healthy
male and female volunteers, using a concentration-
effect analysis on the QTc interval validated by meal
effects. In addition, we assessed the safety, tolera-
bility, and pharmacokinetics (PK) of cortexolone
17α-propionate.
Methods
Study Design and Procedures
This single-center, randomized, double-blind, placebo-
controlled study was conducted at Richmond Phar-
macology (London, UK). The study aimed to assess
the QTc interval in addition to the safety, tolerabil-
ity, and pharmacokinetics of multiple doses of cor-
texolone 17α-propionate in healthy adults. The study
protocol (NCT03665194) was reviewed and approved
by a National Health Service Research Ethics Com-
mittee (London Bridge, UK), and the Medicines and
Healthcare Products Regulatory Authority (London,
UK). The study was conducted according to the ethi-
cal principles enshrined in UK law, the Declaration of
Helsinki, and Good Clinical Practice guidelines.
Study Volunteers
A total of 32 healthy adult volunteers (male and fe-
male, aged 18 to 40 years inclusive, body mass index be-
tween 18.0 and 25.0 kg/m2) were targeted for enrollment
in this study. Volunteers had to be bald, have a shaved
head, or be willing to have their heads shaved and be on
acceptable forms of contraception to be enrolled in this
study.
Written and signed informed consent was obtained
from each participant before taking part in the study.
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Figure 1. Study outline flowchart.
Volunteers were excluded if they had (1) known struc-
tural cardiac abnormalities; (2) a family history of
long QT syndrome; (3) cardiac syncope or recurrent,
idiopathic syncope; (4) exercise-related clinically sig-
nificant cardiac events; or (5) any clinically significant
abnormalities in rhythm, conduction, or morphology
of resting ECG or clinically important abnormalities
that might have interfered with the interpretation of
QTc interval changes. These included but were not
limited to sinus node dysfunction, clinically significant
PR (PQ) interval prolongation, intermittent second- or
third-degree atrioventricular block, complete bundle
branch block, abnormal T-wave morphology, and a
QT interval corrected using the Fridericia’s formula
(QTcF) > 450 milliseconds.
Eligible participants were randomly assigned to a
treatment regimen according to a schedule generated
by an independent statistician using PROC Plan. Vol-
unteers were randomly assigned on day 1 in a 3:1 ratio
to either cortexolone 17α-propionate or matching vehi-
cle placebo.
Procedures
The study outline is shown in Figure 1. The dosing
regimen for 24 volunteers consisted of a morning and
evening dose (12 hours apart) of 225 mg (3 mL) cor-
texolone 17α-propionate applied topically to the scalp
and both thighs as a 7.5% solution (75mg in 1mL), rep-
resenting a total daily dose of 450 mg (6 mL) per par-
ticipant. The cortexolone 17α-propionate dose in this
study was 4.5-fold higher than the highest dose previ-
ously tested in the 28-day multiple-dose study (50 mg
per application) and was chosen to achieve a minimum
2-fold mean exposure relative to the previous study.
In addition, 8 volunteers received a matching vehicle
placebo. Twice-daily dosing was planned on days 1 to
3 followed by a single dose on day 4, all under fed con-
ditions. Matching standard meals were given on days
1 and 4, where breakfast was served 30 minutes prior
to the morning dose; lunch was given 5 hours after
the morning dose, and no other meals were served be-
fore completion of the cardiac assessments 2 to 4 hours
postmeal. Dinner was served 10 hours after the morn-
ing dose.
Pharmacokinetic Assessments
To achieve primary and secondary objectives, blood
samples for plasma pharmacokinetics were collected on
days 1 and 4 at −1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 12 hours,
at −1 hour on days 2 and 3, and 24 and 48 hours fol-
lowing the last dose on day 4. Plasma samples to de-
termine concentrations of cortexolone 17α-propionate
and its main metabolites/degradation products cortex-
olone 21-propionate (M1, Figure S2) and cortexolone
(M2, Figure S3) were analyzed by MicroConstants Inc
(San Diego, California) employing a validated liquid
chromatology-tandem mass spectrometry method with
liquid-liquid extraction. This was developed and sat-
isfactorily validated for the measurements of cortex-
olone 17α-propionate and M1 over a calibration range
of 0.250 to 250 ng/mL and for M2 over the calibration
range of 0.500 to 500 ng/mL. Chromatographic sepa-
ration was performed through a Kinetex XB-C18 (50
× 2.1 mm, Phenomenex, Macclesfield, Cheshire, UK)
analytical column with a mobile phase nebulized us-
ing heated nitrogen in electrospray positive ionization
mode (see Supplement 1). Precision, accuracy, and se-
lectivity of the method were found to be within satis-
factory bounds using validated methods, and no issues
were encountered during the execution of the sample
analysis.
Pharmacokinetic analyses were performed using a
noncompartmental method with SAS software, ver-
sion 9.4 (SAS Institute Inc.,Marlow, Buckinghamshire,
UK).
ECG Cardiac Assessments and QTc Evaluation
Intensive cardiac assessments were performed on days
1 and 4 to achieve our primary objectives. All ECG
recordings were obtained in triplicate at each time (at
1-minute intervals over 3 minutes, lasting 10 seconds
each) and were compliant with the correct recording
and manual adjudication of ECG in thorough QT/QTc
(TQT) studies in accordance with ICH guidelines.14
Twelve-lead ECGs were acquired using a GE
Marquette MAC1200/MAC1200ST (GE Healthcare,
Chicago, Illinois) and stored electronically on the
MUSE information system. Only ECGs recorded elec-
tronically at a stable heart rate (HR) were valid for QT-
interval measurements. ECG recordings were collected
on days 1 and 4 at 2, 1.5, and 1 hours predose and 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, and 12 hours postdose; on days 2
and 3 at 1 hour predose and on day 5 at 24 hours post-
dose. All ECGs were recorded after the volunteers had
been resting in a supine position for at least 10 minutes.
To obtain consistent ECG recordings, the clinical staff
ensured that the volunteers were awake and avoided any
postural changes.
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Each ECG data file contained the ECG data and
the result of the automated ECG analysis performed by
theMarquette 12SL ECGAnalysis Program. All ECGs
and their associated automated interval measurements
were subsequently reviewed by qualified cardiologists in
accordance with the ICH Guidance for Industry doc-
ument and ICH E14 Implementation Working Group
Questions-and-Answers document14 before any of the
ECGs were used for the subsequent statistical analysis.
The uncorrected QT interval, the RR interval,
the HR (derived according to the formula HR =
60 000/RR), the PR interval, QRS duration, the pres-
ence or absence of U waves, and quantitative and qual-
itative ECG variations were assessed by the cardiol-
ogist who had extensive experience with manual on-
screen overreading using electronic calipers in MUSE.
All ECGs were overread by the same cardiologist, who
was blinded to the time, treatment of the recording be-
ing evaluated, and any data identifying an individual,
in accordance with principles set out in the ICH E14
guidelines. If manual adjustments of the automated
measurement became necessary and the first overreader
requested adjudication, then a second cardiologist
performed overreading and assessment. Similarly, if
the second cardiologist requested further adjudication,
then the third most senior cardiologist performed the
assessment. Corrected QT interval (QTcF) was used for
all analyses, as relevant HR changes were not expected.
Both the matching vehicle placebo and active com-
pound dosing data were included in the analysis. A
total of 817 ECGs (26%) were corrected after adjudi-
cation from a total of 3151 ECGs. Predose baseline
values were obtained from 3 predose times (2, 1.5, and
1 hour before drug administration); the mean of the
values obtained at these times was used as baseline.
Statistical Analysis
Analysis of drug-related QT/QTc interval changes rel-
ative to plasma PK concentrations was conducted us-
ing concentration-effect modeling. The principles of
this analysis followed statistical methods previously
described.15,16 Specifically, a primary linear mixed-
effects model was used for the concentration-QTc anal-
ysis based on the change from average predose baseline
that included a fixed time effect and a treatment effect.
Time was presented as a fixed effect, considering that
dosing was repeated on several days. The model had a
centered baseline (ie, baseline minus mean of baseline
across volunteers), in which the mean of baseline across
participants was zero. No fixed intercept was allowed.
Baseline was included in the model as a covariate. The
model had random effects per volunteer for the inter-
cept and the concentration.
The Kenward-Roger approximation (a linear mixed
model that allows for better estimation of precision and
interference for fixed effects in small sample sets)17 was
used to calculate degrees of freedom and any t test-
based quantities, specifically 2-sided 90% confidence in-
tervals for the model parameters. Based on this model,
predictions of the effect of the investigational medici-
nal product onQTcF at concentrations seen in the study
were made. Specifically, predictions of the effect at the
geometric mean of the individual Cmax values were
given together with 2-sided 90% confidence intervals.
A series of models using all possible combinations of
the 3 moieties analyzed, as covariates did not show any
improvement in fit when compared with the model us-
ing only cortexolone 17α-propionate as a covariate, as
measured by the Akaike information criterion. Models
with moieties other than cortexolone 17α-propionate
were, thus, not further explored.
Assay Sensitivity
The effects of a meal on the ECGwere used to establish
assay sensitivity, that is, to confirm that the study was
capable of detecting small changes in QTc. Tests for as-
say sensitivity were performed on the basis of the esti-
mates of the time course of QTcF obtained from the
primary model described above. For the 2- and 3-hour
times on days 1 and 4, the change from predose base-
line for day 1 and the change from the 1-hour predose
values on day 4, respectively, were tested at the 1-sided
5% level. The study was declared to be adequately sensi-
tive to show a small change in meanQTc if a shortening
significant at the 1-sided 5% level could be shown.
Safety Assessments
Adverse events (AEs) were continuously monitored
throughout the study from the date of informed con-
sent until the end of each individual’s participation.
The intensity and potential relationship with the study
drug of each of the reported AEs were assessed. Vol-
unteers underwent physical examinations and clinical
laboratory tests (hematology, coagulation, biochem-
istry, and urinalysis). Telemetry, 12-lead ECGs, blood
pressure (systolic and diastolic), HR, and tempera-
ture were regularly evaluated during the study. Any
clinically significant abnormalities were reported as
AEs. All AEs were graded using the National Cancer
Institute Common Terminology Criteria for Adverse
Events version 4.0 (CTCAE).
Results
Participant Disposition and Demographics
Of the 82 volunteers screened, 50 did not meet the
screening criteria. A total of 32 volunteers fulfilled the
eligibility criteria and were randomized to treatment.
All completed the study and were included in the analy-
sis sets. One volunteer withdrew consent from the study
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Sex Male, n (%) 19 (79.2%) 8 (100.0%)
Female, n (%) 5 (20.8%) 0 (0%)
Race White, n (%) 17 (70.8%) 3 (37.5%)
Hispanic, n (%) 0 (0%) 0 (0%)
Black or African American, n (%) 3 (12.5%) 3 (37.5%)
Asian, n (%) 1 (4.2%) 0 (0%)
Indian/Pakistani, n (%) 0 (0%) 0 (0%)
Other, n (%) 3 (12.5%) 2 (25.0%)
Age (y) n 24 8
Mean ± SD 26.3 ± 6.0 25.4 ± 4.7
Range 18-38 18-31
Weight (kg) n 24 8
Mean ± SD 70.0 ± 9.7 73.5 ± 9.1
Range 53.2-89.1 61.4-86.7
BMI (kg/m2) n 24 8
Mean ± SD 22.4 ± 1.9 22.4 ± 1.5
Range 19.3-25.0 20.6-24.5
SD, standard deviation.
on day 2 after receiving 1 dose. Demographic data and
volunteer disposition are summarized in Table 1.
Single-Dose Pharmacokinetics
After application of single doses, plasma concentration
of cortexolone 17α-propionate rose gradually, which
is likely a reflection of topical absorption, reaching
Tmax at 5 hours (Figure 2). Levels then declined before
plateauing at 6 hours, with no evidence of elimination
during the 12-hour single-dosing period. Plasma con-
centrations of metabolites/degradation products were
not detected (M1) or only marginally rose above the
lower limit of quantification (M2).
Multiple-Dose Pharmacokinetics
Following multiple dosing, plasma concentrations of
cortexolone 17α-propionate rose most markedly be-
tween 12 and 23 hours (representing the second
and third doses, respectively). Concentrations then
plateauedwith Tmax at 77 hours before declining to near
zero at 120 hours (Figure 2). M1 was detected in con-
centrationsmarginally above the lower limit of quantifi-
cation in only 5 participants, at 1 point each. No other
PK parameters were calculated for M1 because of neg-
ligible plasma concentrations. M2 concentrations rose
the most between 12 and 23 hours, reaching Tmax at 48
hours, then fluctuated before plateauing between 96 and
120 hours.
For both cortexolone 17α-propionate and M2, the
ratio of AUC0-24 on day 4 to AUC0-24 on day 1 and the
ratio of Cmax on day 4 to Cmax on day 1 were greater
than 1.0, indicating an accumulation during multiple
dosing. In addition, geometric mean trough values for
M2 rose on day 5 following an initial decline, point-
ing to the continued metabolism of cortexolone 17α-
propionate into M2 after the end of dosing.
Descriptive statistics of PK parameters of cortex-
olone 17α-propionate andM2, comparing mean values
and standard deviations between day 1 and day 4 are
presented in Table 2.
Cardiac Assessments
The primary analysis was conducted following the sta-
tistical methods previously described18 and employed
the change from average baseline of theQT interval cor-
rected for HR using Fridericia’s formula (QTcF).
All the volunteers in the safety data set who had valid
ECGdata for at least 1 postdosing timewere included in
the primary analysis set. A total of 11 values had to be
excluded because the time difference between the ECG
and the blood sampling exceeded the predefined limit.
An increase in HR under active treatment was ob-
served within 5 hours postdose on day 1 and for a num-
ber of times on day 4. There was no indication that
this difference was because of differences at baseline
or a causal relationship with the drug concentration.
Concentration-effect modeling performed on HR data
yielded a negative slope, suggesting that the model did
not fully capture the effect of the drug on heart rate (see
Supplement 2).
Based on the model, predictions of the effect of cor-
texolone 17α-propionate on QTcF at concentrations
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Figure 2. Mean (SD) of plasma concentrations of cortexolone 17α-propionate—single dose (A) and multiple dose (B)—and cor-
texolone (M2)—single dose (C) and multiple dose (D).
seen in the studyweremade. The prediction of the effect
at the geometric mean of the individual Cmax values is
shown in Table 3, highlighting a negative estimate.
The estimates of the time course analysis derived
from the primary model are shown in Figure 3. “Time
effect” refers to variations in duration of QTc through-
out the day and represents fluctuations not caused by
drug administration. All estimates were negative, rang-
ing from −13.6 to −1.1 milliseconds. All postdose 90%
confidence intervals were negative based on the model.
The relationship between QTcF and the cortexolone
17α-propionate plasma concentration showed that the
majority of the effect observed was because of the meal
effect. There was a small but nonsignificant shortening
effect at some points because of the effect of the drug
(Figure 4).
Sensitivity of the Assay
The sensitivity of the assessment to consistently detect
changes of QTcFwas established by observing the meal
effect. Providing a meal and then observing a small
shortening of QTc 2 to 4 hours later demonstrate the
ability of the experiment to detect small changes in QTc
duration. The change from baseline of the time effect
in the primary linear model for day 1 and from 1 hour
predose on day 4, provided the opportunity to evalu-
ate assay sensitivity on each of the 2 ECG assessment
days (Table 4). All 95% confidence intervals were nega-
tive, with point estimates around−5milliseconds or be-
low and the 95%CI < 0. This corresponds to the upper
limit of the 2-sided 90%CI, and therefore assay sensi-
tivity was considered shown.
Safety Assessments
A total of 12 adverse events (AEs) were reported in 9
participants who had all received the study medication.
No volunteers given the vehicle placebo reported any
AEs. Of the 12 AEs reported, 6 were considered related
to study medication.
The most common system organ class for AEs relat-
ing to study medication was skin and subcutaneous tis-
sue disorders and nervous systemdisorders. Therewas 1
pretreatment AE (skin exfoliation). All other AEs were
treatment-emergent.
All AEs were graded as mild (CTCAE grade I), ex-
cept for a migraine, which was graded as moderate (CT-
CAEgrade II) andwas considered related to studymed-
ication. All AEs had resolved without sequelae by the
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Table 2. Descriptive Statistics of PK Parameters of Cortexolone 17α-Propionate and Cortexolone (M2)
Cortexolone 17α-Propionate Cortexolone (M2)
Parameter Day 1 (Hours 0-24) Day 4 (Hours 72-96) Day 1 (Hours 0-24) Day 4 (Hours 72-96)














NC 11.24 ± 3.31
(n = 8)
















AUC0-inf (ng·h/mL), mean ± SD NC 219.34 ± 92.03
(n = 20)
NC 110.83 ± 42.64
(n = 7)








Half-life λ z (h) NC 26.80 ± 14.60
(n = 20)
NC 90.10 ± 53.70
(n = 7)
NC, not calculated; SD, standard deviation.
If data did not rise above the lower limit of quantitation, it was not included in the calculation of descriptive statistics.
Table 3. Prediction of the Effect at the Geometric Mean Cmax of Cortexolone 17α-Propionate
Concentration Predicted Effect on QTcF (ms)
(ng/mL) Estimate SE df t 90% Confidence Interval
6.602 −0.45 2.11 35.2 −0.21 −4.0 3.1
df, degrees of freedom; SE, standard error.
Table 4. Change From Baseline of the Time Effect in the Primary Linear Model for Day 1 and From−1Hour on Day 4 to Demonstrate
Assay Sensitivity
Time Estimate SE df t 90% Confidence Interval
D1 2 h −10.1 1.35 83.9 −7.44 −12.3 −7.8
D1 3 h −8.2 1.37 87.9 −5.98 −10.5 −5.9
D4 2 h −4.4 1.32 725.0 −3.37 −6.6 −2.3
D4 3 h −4.7 1.31 725.1 −3.60 −6.9 −2.6
D, day; df, degrees of freedom; SE, standard error.
end of the study. No serious AEs were reported in this
study, and noAEs that led to an individual withdrawing
from the study.
Discussion
Cortexolone 17α-propionate has been designed for the
topical treatment of AGA and acne—both of which
are conditions that typically require long-term use of
medication under minimal medical supervision. This
study was prompted by in vitro preclinical studies
showing a mild hERG inhibition. Because cortexolone
17α-propionate is a topical preparation, volunteers
were able to apply the medication more frequently or to
a larger area than prescribed, causing supratherapeutic
exposures.
Because the in vitro effect on hERG inhibition was
mild, and no QT effect was observed in prior clinical
studies,2 the initial likelihood of QT prolongation
for cortexolone 17α-propionate was low. However,
because of the cosmetic indications of cortexolone
17α-propionate and the opportunity for long-term use
in the absence of medical monitoring, we sought to
assess QT prolongation at supratherapeutic systemic
exposures to determine beyond a reasonable doubt,
that the medication is safe for long-term use at home
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Figure 3. Estimates of the time course analysis derived from
the primary model for day 1 (red) and day 4 (blue).
Figure 4. Raw values of QTcF versus plasma concentration
of cortexolone 17α-propionate with regression line (slope, 0.13
adjusted for the average time effect to match the data displayed).
The slight,nonsignificant positive correlation shows cortexolone
17α-propionate has no effect on QTc.
without supervision. By the upper end of the 2-sided
90% confidence interval for the cortexolone 17α-
propionate concentration-effect model falling below 10
milliseconds,17 this study has established the cardiac
safety of cortexolone 17α-propionate.
Given that the tested medication resulted in minimal
systemic exposure when applied at therapeutic doses,
one of our major considerations in designing this study
was to achieve the necessary supratherapeutic expo-
sures. Therefore, a stronger 7.5% solution formulation
was used and applied to both thighs in addition to the
scalp to maximize the surface area for absorption. Us-
ing a higher-concentration solution, the results of this
study also apply to the standard cream formulation.
To achieve regulatory acceptance as a QT study
for both the cream and solution formulations, we also
needed to demonstrate assay sensitivity or the ability
to detect small changes in QT intervals. To this end,
a standardized meal was used because the food effect
has been shown to shorten the QT interval and is an es-
tablished alternative to a pharmacological positive con-
trol arm—usually moxifloxacin.19–21 At all times, the
2-sided 90% confidence interval was negative, meaning
the study methodology could detect the QT-shortening
effect of a meal on volunteers, thereby confirming as-
say sensitivity. The results demonstrate this study’s abil-
ity to detect QTcF changes at the 5-millisecond thresh-
old of regulatory interest.17 The results also support the
use of a meal as a nontoxic alternative to a pharmaco-
logical positive control to demonstrate assay sensitivity
in QTc assessments in line with results from previous
studies.21–23
By achieving a greater than 2-fold increase in ex-
posures relative to the anticipated therapeutic dose,
the study meets ICH E14 requirements for acceptance
as an alternative to a TQT study.23 In the absence of
procedural differences between this study and the pre-
vious one,1 doses of cortexolone 17α-propionate being
4.5-fold greater than previously tested1 may have been
achieved by requiring volunteers to keep the solution
on their skin for a longer time before washing. Typi-
cally, fewer than 2% of similar topical preparations are
absorbed systemically when applied for a whole day.24
To allow for a more homogeneous administration and
more reproducible PK assessments, the heads and legs
(if hairy) of volunteers were shaved. This presents a
possible limitation, as previous research has shown that
hair follicles are an important route of absorption for
many topical compounds and can act as reservoirs for
target drugs.25,26 Conversely, some authors have argued
that shaving may enhance percutaneous penetration
of select compounds because it removes the stratum
corneum,27 which, when intact, acts as a rate-limiting
barrier to topical drug absorption.28 Indeed, shaving
may have enhanced the reproducibility of our find-
ings, yet future assessments are needed to verify the
consistency of our results when applied to nonshaven
sites.
There are also limits to the use of a suprathera-
peutic dose for maximizing systemic exposures, as the
doses administered in this study may have reached the
maximum threshold for percutaneous absorption of
Täubel et al 9
cortexolone 17α-propionate, meaning that the skin was
saturated with study medication and that higher doses
would not have resulted in higher exposures.
The absence of QT prolongation for cortexolone
17α-propionate seen in this study is consistent with
existing research on antiandrogenic therapy11 and glu-
cocorticoids, which conversely suggest a QT-shortening
effect of glucocorticoids at therapeutic doses because
of the role of glucocorticoid signaling in cardiac
myocytes,12,13 albeit at therapeutic glucocorticoid
doses with systemic exposures that were likely far
greater than those achieved in this study. Our findings
suggest that although antiandrogenic drugs such as cor-
texolone 17α-propionate are physiologically capable
of exerting effects on the duration of QTc, a stan-
dard topical application would not achieve a plasma
concentration high enough to induce any cardiac
effect.
Conclusion
This study met the regulatory requirements for a neg-
ative QT study, with the upper end of the 2-sided 90%
confidence interval for a change in QTcF falling below
10 milliseconds at the supratherapeutic doses tested.
The effect of ameal on theQTc interval was successfully
employed as a positive control to demonstrate assay
sensitivity. Cortexolone 17α-propionate has previously
been shown to be generally well tolerated in healthy
male and female volunteers, with the most common
AEs being of mild severity and local to the application
site. In conclusion, our results show that cortexolone
17α-propionate and its metabolites/degradation prod-
ucts are tolerated at supratherapeutic doses and are not
associated with clinically meaningful QTcF prolonga-
tion.
Acknowledgments
The authors thank all the volunteers participating in this
study. The authors thank Cassiopea SpA for funding the
study and providing feedback and experimental conception.
Special thanks are extended to the clinical and support staff at
Richmond Pharmacology Ltd for their invaluable assistance
in the execution of the clinical study.
Conflicts of Interest
J.T., W.B., S.F., and A.P. are employees of Richmond Phar-
macology Ltd. G.F. is an employee of Statistik Georg Fer-
ber GmbH who has received honoraria for consulting from
Richmond Pharmacology. C.S. and A.F. are employees of the
Richmond Research Institute. A.M. is an employee of Cas-
siopea SpA.
Funding
Clascoterone is being developed by Cassiopea SpA. Cassio-
pea SpA funded this clinical trial to investigate Clascoterone.
Contributors
A.M. and J.T. conceived the study. W.B., A.M., and J.T. were
involved in the data interpretation. C.S. and A.F. prepared
and edited the manuscript. All authors were involved in the
drafting of the manuscript. All authors approved the final
submitted version and agreed to the publication.
Data Sharing
Requests for access to data should be addressed to the corre-
sponding author.
References
1. Ferraboschi P, Legnani L, CelascoG,Moro L, Ragonesi
L, Colombo D. A full conformational characteriza-
tion of antiandrogen cortexolone-17α-propionate and
related compounds through theoretical calculations and
nuclear magnetic resonance spectroscopy. MedChem-
Comm. 2014;5(7):904-914.
2. Jonklaas J, Holst J, Verbalis J, Pehlivanova M, Soldin
S. Changes in steroid concentrations with the timing
of corticotropin stimulation testing in participants with
adrenal sufficiency. Endocr Pract. 2012;18(1):66-75.
3. Chen C, Puy LA, Simard J, Li X, Singh SM, Labrie F.
Local and systemic reduction by topical finasteride or
flutamide of hamster flank organ size and enzyme activ-
ity. J Invest Dermatol. 1995;105(5):678-682.
4. Sintov A, Serafimovich S, Gilhar A. New topical an-
tiandrogenic formulations can stimulate hair growth in
human bald scalp grafted onto mice. Int J Pharm.
2000;194(1):125-134.
5. Marks DH, Prasad S, De Souza B, Burns LJ, Senna
MM. Topical antiandrogen therapies for androgenetic
alopecia and acne vulgaris. Am J Clin Dermatol.
2020;21(2):245-54.
6. Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro
L, Celasco G. Cortexolone 17α-propionate 1% cream, a
new potent antiandrogen for topical treatment of acne
vulgaris. A pilot randomized, double-blind comparative
study vs. placebo and tretinoin 0·05% cream. Br J Der-
matol. 2011;165(1):177-183.
7. Priest B, Bell IM, Garcia M. Role of hERG potas-
sium channel assays in drug development. Channels.
2008;2(2):87-93.
8. Vink AS, Clur S-AB,Wilde AA, BlomNA. Effect of age
and gender on the QTc-interval in healthy individuals
and patients with long-QT syndrome. Trends Cardiovasc
Med. 2018;28(1):64-75.
9. Abehsira G, Bachelot A, Badilini F, et al. Complex
influence of gonadotropins and sex steroid hormones
10 Clinical Pharmacology in Drug Development 2021, 0(0)
on QT interval duration. J Clin Endocrinol Metab.
2016;101(7):2776-2784.
10. Lubart E, Yarovoy A, Gal G, Krakover R, Leibovitz
A. QT interval length in elderly prostatic cancer pa-
tients on anti-testosterone treatment. Isr Med Assoc J.
2015;17(6):356-359.
11. Suzuki R, Hayashi T, Asano H, Ohashi K, Sakamoto
M. Prolonged QT intervals in isolated ACTH deficiency:
Case Report and Mini Review of Literature. J Steroids
Horm Sci. 2016;7(176):2.
12. Saribayev M, Tufan F, Oz F, et al. Corticosteroid
treatment normalizes QTc prolongation and improves
heart block in an elderly patient with anti-Ro-positive
systemic lupus erythematosus. Aging Clin Exp Res.
2014;26(3):337-339.
13. Celasco G, Piacquadio D, Moro L. Cortexolone 17a-
propionate: preclinical profile of a new topical, skin se-
lective, steroidal antiandrogen. J Am Acad Dermatol.
2012;66(4).
14. ICH E14 Guideline: The Clinical Evaluation of QT/QTc
Interval Prolongation and Proarrhythmic Potential for
Non-Antiarrhythmic Drugs Questions & Answers (R3)
2015 [2/6/2016]. 61134]. In:2015.
15. Garnett C, Needleman K, Liu J, Brundage R, Wang
Y. Operational characteristics of linear concentration-
QT models for assessing QTc interval in the thorough
QT and phase I clinical studies. Clin Pharmacol Ther.
2016;100(2):170-178.
16. Ferber G, Wang D, Täubel J. Concentration–effect
modeling based on change from baseline to assess the
prolonging effect of drugs on QTc together with an
estimate of the circadian time course. J Clin Pharmacol.
2014;54(12):1400-1406.
17. Kenward MG, Roger JH. Small sample inference for
fixed effects from restricted maximum likelihood. Bio-
metrics. 1997;53(3):983-997.
18. Täubel J, Fernandes S, Ferber G. Stability of the effect
of a standardized meal on QTc. Ann Noninvasive Elec-
trocardiol. 2017;22(1):e12371.
19. Cirincione B, Sager PT, Mager DE. Influence of meals
and glycemic changes on QT interval dynamics. J Clin
Pharmacol. 2017;57(8):966-976.
20. Garnett C, Bonate PL, Dang Q, et al. Scientific white
paper on concentration-QTcmodeling. J Pharmacokinet
Pharmacodyn. 2018;45(3):383-397.
21. Täubel J, Ferber G, Lorch U, Wang D, Sust M, Camm
AJ. Single doses up to 800 mg of E-52862 do not
prolong the QTc interval–a retrospective validation by
pharmacokinetic-pharmacodynamic modelling of elec-
trocardiography data utilising the effects of a meal on
QTc to demonstrate ECG assay sensitivity. PLoS One.
2015;10(8):e0136369.
22. Täubel J, Ferber G, Fernandes S, Santamaria E,
Izquierdo I. Cardiac safety of rupatadine in a single-
ascending-dose and multiple-ascending-dose study in
healthy Japanese subjects, using intensive electrocardio-
gram assessments—comparison with the previous white
Caucasian thorough QT study. Clin Pharmacol Drug
Dev. 2018;7(1):67-76.
23. Täubel J, Lorch U, Coates S, et al. Confirmation of the
cardiac safety of PGF2α receptor antagonist OBE022
in a first-in-human study in healthy subjects, using in-
tensive ECG assessments. Clin Pharmacol Drug Dev.
2018;7(8):889-900.
24. Dhar S, Seth J, ParikhD. Systemic side-effects of topical
corticosteroids. Indian J Dermatol. 2014;59(5):460.
25. Otberg N, Patzelt A, Rasulev U, et al. The role of hair
follicles in the percutaneous absorption of caffeine. Br J
Clin Pharmacol. 2008;65(4):488-492.
26. Leite-Silva VR, de Almeida MM, Fradin A, Grice JE,
Roberts MS. Delivery of drugs applied topically to the
skin. Expert Rev Dermatol. 2012;7(4):383-397.
27. Baker H, Kligman AM. Technique for estimating
turnover time of human stratum corneum. Arch Derma-
tol. 1967;95(4):408-411.
28. NgK, Penetration enhancement of topical formulations.
Pharmaceutics. 2018;10(2):51.
Supplemental Information
Additional supplemental information can be found by click-
ing the Supplements link in the PDF toolbar or the Supple-
mental Information section at the end of web-based version
of this article.
